Publications by authors named "Mathilde Gheysen"
Article Synopsis
- Primary and acquired endocrine resistance complicates treatment for hormone receptor positive breast cancer, often due to mutations in estrogen receptor 1 (ESR1) that cause estrogen-independent activation.
- Selective estrogen receptor degraders (SERDs) are a new class of drugs that can degrade the ESR1 receptor, showing promise against this resistance, particularly in oral formulations that are more potent than the original intramuscular drug, fulvestrant.
- Clinical trials, like the EMERALD trial for elacestrant and SERENA-2 for camizestrant, showed improved progression-free survival (PFS), particularly after prior treatments, while other SERDs like giredestrant and amcenestrant did not demonstrate this benefit
Depression is a common and disabling disorder in later life, particularly among people with poor physical health. There are many screening tools available that can be used to examine depressive symptoms; however, not all of them may be appropriate or accurate for older adults with cancer. This pilot study was designed to test the diagnostic performance of two screening tools and their short versions in a cohort of vulnerable (G8 score ≤ 14/17) older patients with cancer undergoing comprehensive geriatric assessment (CGA).
View Article and Find Full Text PDFIntroduction: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract and the most frequent sarcomas in some geographic regions. In patients with metastatic GIST, the tyrosine kinase inhibitor imatinib is the first-line standard of care. Mutations in KIT or specific platelet-derived growth factor receptor alpha (PDGFRA) gene aberrations in the tumor cells predict a favorable response to this agent, while tumors without KIT or PDGFRA mutations ("wild-type" GISTs) are usually resistant to such treatment.
View Article and Find Full Text PDF